

West Yorkshire Integrated Care Board (WY ICB)

Policy	Rhinophyma			ICB Ref	Planned care
First Issue Date	To be confirmed	Current version:	1	Last reviewed:	May 2022
Review date	To be confirmed	Contact	West Yorkshire Health and Care Partnership (WY HCP) wyhcp.plannedcare@nhs.net		
Clinical Reviewer	WY HCP	Approved by	WY ICB		

Policy exclusions

Rhinophyma is a progressive skin condition that affects the nose. The condition is mainly seen in those who have rosacea, a rash that can affect the cheeks, forehead and nose (British Association of Dermatologists [get-file.ashx \(bad.org.uk\)](http://get-file.ashx(bad.org.uk)))

Treatments/interventions for the treatment of Rhinophyma are not routinely commissioned.

Patients who have regular, well documented episodes of eruptions of foul smelling discharge and or bleeding with a Dermatology Life Quality Index of >10 do not need to seek prior approval for treatment.

Policy inclusion criteria

Treatment for Rhinophyma is not routinely commissioned. Any requests that are not medically necessary are considered cosmetic and will not be funded. These treatments may be considered on an individual, exceptional basis, where the GP or consultant has completed the necessary Individual Funding Request form.

Rhinophyma with very significant phymatous change (where isotretinoin unlikely to be effective), laser treatment, shave excision or shave diathermy may be funded by prior approval or on an exceptional basis where all the below are met:

- There is photographic evidence of significant distortion.

AND

- A Dermatology Life Quality Index (DLQI) score ≥ 10

AND

- Condition has not responded to first line treatment of rosacea

AND

- Following recommendation from a Consultant Dermatologist.

An enhancement for people living in Bradford District and Craven where no policy currently exists and for them and all other people in West Yorkshire, it allows patients who have regular, well documented episodes of eruptions of foul smelling discharge and or bleeding with a Dermatology Life Quality Index of >10 to be able to access treatment without seeking prior approval.

Summary of evidence / Rationale	<ol style="list-style-type: none"><li data-bbox="491 123 1442 309">1. A nationally produced information leaflet on Rhinophyma from the British Association of Dermatologists; https://www.skinhealthinfo.org.uk/wp-content/uploads/2018/11/Rhinophyma-Update-February-2018-Lay-reviewed-Janauary-2018.pdf<li data-bbox="491 315 1442 488">2. Information for Commissioners of Plastic Surgery Services. Referrals and Guidelines in plastic surgery (PDF); http://www.bapras.org.uk/docs/default-source/commissioning-and-policy/information-for-commissioners-of-plastic-surgery-services.pdf?sfvrsn=2
--	---